Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ALKS.O
stocks logo

ALKS.O

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
378.57M
-11.96%
0.402
-61.72%
378.72M
+23.56%
0.380
+30.58%
473.70M
+21.26%
0.600
-11.6%
Estimates Revision
The market is revising Upward the revenue expectations for Alkermes plc (ALKS) for FY2025, with the revenue forecasts being adjusted by 3.59% over the past three months. During the same period, the stock price has changed by 4.32%.
Revenue Estimates for FY2025
Revise Upward
up Image
+3.59%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+13.05%
In Past 3 Month
Stock Price
Go Up
up Image
+4.32%
In Past 3 Month
Wall Street analysts forecast ALKS.O stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALKS.O is 43.33 USD with a low forecast of 34.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
Wall Street analysts forecast ALKS.O stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALKS.O is 43.33 USD with a low forecast of 34.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
5 Hold
0 Sell
Moderate Buy
Current: 29.330
sliders
Low
34.00
Averages
43.33
High
50.00
Current: 29.330
sliders
Low
34.00
Averages
43.33
High
50.00
Deutsche Bank
David Hoang
Buy
downgrade
$55 -> $45
2025-11-13
New
Reason
Deutsche Bank
David Hoang
Price Target
$55 -> $45
2025-11-13
New
downgrade
Buy
Reason
Deutsche Bank analyst David Hoang lowered the firm's price target on Alkermes to $45 from $55 and keeps a Buy rating on the shares. The company announced positive topline data from its Phase 2 VIBRANCE-2 trial of alixorexton in narcolepsy type 2, but results came in below the high expectations needed for the drug to be a "clear best-in-class therapy," the analyst tells investors in a research note. The firm believes the shares dropped yesterday on a perceived less competitive commercial profile for alixorexton versus peers.
Truist
Joon Lee
Buy
maintain
$50
2025-11-12
Reason
Truist
Joon Lee
Price Target
$50
2025-11-12
maintain
Buy
Reason
Truist analyst Joon Lee says that while Alkermes announced the dual endpoints were met in the Vibrance-2 dose-ranging Phase 2 study evaluating alixorexton in patients with narcolepsy type 2, the "details are scant." Truist is "comforted" that 95% of patients chose to enter the optional five-week open-label extension, which it believes speaks to a good benefit/risk ratio. The firm has a Buy rating on Alkermes with a $50 price target. The stock in morning trading is down 12%, or $3.94, to $29.88.
Evercore ISI
Evercore ISI
Outperform
maintain
$30.47
2025-11-12
Reason
Evercore ISI
Evercore ISI
Price Target
$30.47
2025-11-12
maintain
Outperform
Reason
Evercore ISI said the firm disagrees with the Street reaction on Alkermes (ALKS), adding that the "Street has had a confused reaction to all the new data out of Alkermes and Centessa recently." While the Street thinks the company missed the 20 minute MWT within the arm or greater than 10 minute MWT bar versus placebo, the firm contends "they didn't" and added that Alkermes avoided the "disaster scenario" of failing in narcolepsy type 2 like Takeda's (TAK) TAK-861. The firm, which thinks the Street is "grossly underestimating the clinician interest in this category for narcolepsy," has an Outperform rating on Alkermes shares, which are down $3.34, or 10% to $30.47 in morning trading.
BofA
Jason Gerberry
Neutral
maintain
$33 -> $34
2025-10-28
Reason
BofA
Jason Gerberry
Price Target
$33 -> $34
2025-10-28
maintain
Neutral
Reason
BofA analyst Jason Gerberry raised the firm's price target on Alkermes to $34 from $33 and keeps a Neutral rating on the shares following what the firm calls "a good beat/raise 3Q." While Q3 results were "solid," the firm continues to see the upcoming Vibrance-2 readout in narcolepsy type-2 in November as "a stock driver," says the analyst, who raised the firm's FY25 and onward topline estimates by 1%-2% given strength in the base business.
Mizuho
Outperform
maintain
$40 -> $45
2025-10-27
Reason
Mizuho
Price Target
$40 -> $45
2025-10-27
maintain
Outperform
Reason
Mizuho raised the firm's price target on Alkermes (ALKS) to $45 from $40 and keeps an Outperform rating on the shares. The firm views the acquisition of Avadel (AVDL) as "strategically synergistic." The deal positions Alkermes as a leading player in sleep medicine, the analyst tells investors in a research note. Mizuho does not believe the timing of the deal signals Alkermes is losing confidence in the alixorexton program. It still expects competitive data in November.
RBC Capital
Outperform
maintain
$45 -> $47
2025-10-23
Reason
RBC Capital
Price Target
$45 -> $47
2025-10-23
maintain
Outperform
Reason
RBC Capital raised the firm's price target on Alkermes to $47 from $45 and keeps an Outperform rating on the shares. The company's acquisition of Avadel Pharmaceuticals (AVDL) checks multiple boxes - supporting a key future growth driver with a commercial base of operations, bringing in near-term revenues, and not stretching the balance sheet, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Alkermes Plc (ALKS.O) is 14.36, compared to its 5-year average forward P/E of 96.08. For a more detailed relative valuation and DCF analysis to assess Alkermes Plc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
96.08
Current PE
14.36
Overvalued PE
245.71
Undervalued PE
-53.55

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
4.39
Current EV/EBITDA
10.11
Overvalued EV/EBITDA
77.81
Undervalued EV/EBITDA
-69.03

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Overvalued
5Y Average PS
3.95
Current PS
29.04
Overvalued PS
7.07
Undervalued PS
0.82
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ALKS.O News & Events

Events Timeline

(ET)
2025-11-17
06:11:58
Avadel board determines Lundbeck's proposal is better than Alkermes' offer
select
2025-11-14 (ET)
2025-11-14
12:50:17
Truist believes Alkermes can present a counteroffer that the Avadel board will find acceptable.
select
2025-11-14
12:02:12
Alkermes Experiences a 5.8% Decline
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
11-17Globenewswire
PinnedAvadel Board of Directors Designates Lundbeck Proposal as a "Company Superior Proposal"

  • Lundbeck Proposal Overview: Avadel Pharmaceuticals received an unsolicited acquisition proposal from H. Lundbeck A/S, valuing the company at up to $23.00 per share, totaling approximately $2.4 billion, which represents a 29% premium over its recent stock price.

  • Negotiation Period with Alkermes: Following the proposal, Avadel's Board determined it constitutes a "Company Superior Proposal" under its existing agreement with Alkermes, triggering a five-day negotiation period for potential adjustments to the Alkermes transaction.

  • Conditions and Approvals: The Lundbeck proposal includes cash payments and contingent value rights based on future sales of specific products, and it is subject to shareholder and regulatory approvals.

  • Current Status: Avadel's Board has not changed its recommendation regarding the Alkermes acquisition, and no action is required from Avadel shareholders at this time while discussions with Alkermes are ongoing.

[object Object]
Preview
8.5
11-15Benzinga
Lundbeck's Increased Acquisition Offer Poses Challenge to Alkermes' $2 Billion Avadel Agreement

  • Lundbeck Proposal: Avadel Pharmaceuticals received an unsolicited offer from H. Lundbeck A/S for up to $23.00 per share, which includes $21 in cash and a contingent value right for additional payments.

  • Board's Response: Avadel's Board of Directors believes the Lundbeck proposal could be a "Company Superior Proposal" compared to its existing agreement with Alkermes, which values Avadel at approximately $2.1 billion.

  • Current Stock Performance: Following the news, Avadel's shares rose by 20.22% to $23.13, reaching a new 52-week high.

  • Ongoing Agreement with Alkermes: While the board is open to discussions with Lundbeck, it has not deemed the proposal superior nor has it withdrawn support for the Alkermes acquisition.

[object Object]
Preview
8.5
11-14WSJ
H. Lundbeck Initiates Offer for Avadel to Disrupt Alkermes Agreement

  • Lundbeck's Bid: Danish drugmaker H. Lundbeck has made an unsolicited bid for Avadel Pharmaceuticals valued at up to $2.25 billion.

  • Potential Impact on Acquisition: This bid could disrupt Avadel's existing agreement to be acquired by Alkermes, which offered $18.50 per share plus contingent value rights.

  • Board's Assessment: Avadel's board believes Lundbeck's proposal, which includes $21 per share and additional contingent value rights, may be a superior offer compared to Alkermes' deal.

  • Financial Details: Lundbeck's offer includes cash and contingent value rights that could add up to an additional $2 per share, enhancing the overall value of their proposal.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Alkermes Plc (ALKS.O) stock price today?

The current price of ALKS.O is 29.33 USD — it has increased 1 % in the last trading day.

arrow icon

What is Alkermes Plc (ALKS.O)'s business?

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

arrow icon

What is the price predicton of ALKS.O Stock?

Wall Street analysts forecast ALKS.O stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALKS.O is 43.33 USD with a low forecast of 34.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Alkermes Plc (ALKS.O)'s revenue for the last quarter?

Alkermes Plc revenue for the last quarter amounts to 394.19M USD, increased 4.24 % YoY.

arrow icon

What is Alkermes Plc (ALKS.O)'s earnings per share (EPS) for the last quarter?

Alkermes Plc. EPS for the last quarter amounts to 0.49 USD, decreased -10.91 % YoY.

arrow icon

What changes have occurred in the market's expectations for Alkermes Plc (ALKS.O)'s fundamentals?

The market is revising Upward the revenue expectations for Alkermes plc (ALKS) for FY2025, with the revenue forecasts being adjusted by 3.59% over the past three months. During the same period, the stock price has changed by 4.32%.
arrow icon

How many employees does Alkermes Plc (ALKS.O). have?

Alkermes Plc (ALKS.O) has 1800 emplpoyees as of November 18 2025.

arrow icon

What is Alkermes Plc (ALKS.O) market cap?

Today ALKS.O has the market capitalization of 4.84B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto Tracker
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free